Michael A Bookman

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. ncbi request reprint Standard treatment in advanced ovarian cancer in 2005: the state of the art
    M A Bookman
    Division of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Int J Gynecol Cancer 15:212-20. 2005
  2. ncbi request reprint Is there still a role for hormonal therapy?
    M A Bookman
    Division of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Int J Gynecol Cancer 15:291-7. 2005
  3. pmc Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup
    Michael A Bookman
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 27:1419-25. 2009
  4. ncbi request reprint Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group
    Michael A Bookman
    Division of Medical Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Gynecol Oncol 103:473-8. 2006
  5. doi request reprint First-line randomized trials: revisiting the Ptolemaic universe
    M A Bookman
    Division of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Int J Gynecol Cancer 18:47-52. 2008
  6. ncbi request reprint Developmental chemotherapy and management of recurrent ovarian cancer
    Michael A Bookman
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 21:149s-167s. 2003
  7. pmc Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study
    Robert A Burger
    Robert A Burger, Fox Chase Cancer Center, Philadelphia, PA Mark F Brady, GOG Statistical and Data Center, Buffalo, NY Michael A Bookman, Arizona Cancer Center, Tucson, AZ Bradley J Monk, University of California at Irvine, Orange, CA Joan L Walker, University of Oklahoma, Oklahoma City, OK Howard D Homesley, Wake Forest University Medical Center, Winston Salem, NC Jeffrey Fowler, Ohio State University, Columbus, OH Benjamin E Greer, University of Washington Medical Center, Seattle, WA Matthew Boente, Minnesota Oncology Hematology, Minneapolis, MN Gini F Fleming, University of Chicago, Chicago, IL Peter C Lim, Center of Hope at Renown Regional Medical Center, Reno, NV Stephen C Rubin, University of Pennsylvania Cancer Center, Philadelphia, PA Noriyuki Katsumata, Saitama Medical University International Medical Center GOG Japan, Saitama, Japan and Sharon X Liang, North Shore University Hospital, Manhasset, USA
    J Clin Oncol 32:1210-7. 2014
  8. pmc Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer
    Robert A Burger
    Fox Chase Cancer Center, Philadelphia, PA, USA Electronic address
    Gynecol Oncol 131:21-6. 2013
  9. pmc Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group
    Mark A Morgan
    Section of Gynecologic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Gynecol Oncol 110:329-35. 2008
  10. ncbi request reprint Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182)
    Michael A Bookman
    Division of Medical Science, Fox Chase Cancer Center, Philadelphia, PA 19046, USA
    Semin Oncol 29:20-31. 2002

Detail Information

Publications37

  1. ncbi request reprint Standard treatment in advanced ovarian cancer in 2005: the state of the art
    M A Bookman
    Division of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Int J Gynecol Cancer 15:212-20. 2005
    ..While not an exhaustive review, this study will focus on key clinical concepts that are guiding ovarian cancer research and treatment...
  2. ncbi request reprint Is there still a role for hormonal therapy?
    M A Bookman
    Division of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Int J Gynecol Cancer 15:291-7. 2005
    ..As such, it is reasonable to consider a number of potential hormonal interventions related to the prevention and treatment of ovarian cancer...
  3. pmc Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup
    Michael A Bookman
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 27:1419-25. 2009
    ....
  4. ncbi request reprint Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group
    Michael A Bookman
    Division of Medical Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Gynecol Oncol 103:473-8. 2006
    ..Selection of a feasible sequence and schedule of carboplatin in combination with topotecan for evaluation in advanced epithelial ovarian cancer (EOC)...
  5. doi request reprint First-line randomized trials: revisiting the Ptolemaic universe
    M A Bookman
    Division of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Int J Gynecol Cancer 18:47-52. 2008
    ..Rapid developments in molecular-targeted therapy are challenging our paradigm for future clinical trials, and our priorities need to be carefully considered...
  6. ncbi request reprint Developmental chemotherapy and management of recurrent ovarian cancer
    Michael A Bookman
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 21:149s-167s. 2003
    ....
  7. pmc Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study
    Robert A Burger
    Robert A Burger, Fox Chase Cancer Center, Philadelphia, PA Mark F Brady, GOG Statistical and Data Center, Buffalo, NY Michael A Bookman, Arizona Cancer Center, Tucson, AZ Bradley J Monk, University of California at Irvine, Orange, CA Joan L Walker, University of Oklahoma, Oklahoma City, OK Howard D Homesley, Wake Forest University Medical Center, Winston Salem, NC Jeffrey Fowler, Ohio State University, Columbus, OH Benjamin E Greer, University of Washington Medical Center, Seattle, WA Matthew Boente, Minnesota Oncology Hematology, Minneapolis, MN Gini F Fleming, University of Chicago, Chicago, IL Peter C Lim, Center of Hope at Renown Regional Medical Center, Reno, NV Stephen C Rubin, University of Pennsylvania Cancer Center, Philadelphia, PA Noriyuki Katsumata, Saitama Medical University International Medical Center GOG Japan, Saitama, Japan and Sharon X Liang, North Shore University Hospital, Manhasset, USA
    J Clin Oncol 32:1210-7. 2014
    ..To evaluate risk factors for GI adverse events (AEs) within a phase III trial of bevacizumab in first-line ovarian cancer therapy...
  8. pmc Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer
    Robert A Burger
    Fox Chase Cancer Center, Philadelphia, PA, USA Electronic address
    Gynecol Oncol 131:21-6. 2013
    ..CP alone. To determine the reliability of Response Evaluation Criteria in Solid Tumors (RECIST) in assessing disease progression (PD) in GOG-0218, an independent review of radiologic and clinical data (IRC) was conducted...
  9. pmc Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group
    Mark A Morgan
    Section of Gynecologic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Gynecol Oncol 110:329-35. 2008
    ....
  10. ncbi request reprint Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182)
    Michael A Bookman
    Division of Medical Science, Fox Chase Cancer Center, Philadelphia, PA 19046, USA
    Semin Oncol 29:20-31. 2002
    ..The selection of candidate regimens for this trial illustrates the challenges of drug development in EOC...
  11. ncbi request reprint Incorporation of bevacizumab in the primary treatment of ovarian cancer
    Robert A Burger
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    N Engl J Med 365:2473-83. 2011
    ..Bevacizumab, a humanized anti-vascular endothelial growth factor monoclonal antibody, has shown single-agent activity in women with recurrent tumors. Thus, we aimed to evaluate the addition of bevacizumab to standard front-line therapy...
  12. ncbi request reprint Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy
    R J Schilder
    Fox Chase Cancer Center, Philadelphia, PA, USA
    J Clin Oncol 19:1183-94. 2001
    ..This approach remains experimental and should be used only in the context of a clinical trial...
  13. ncbi request reprint Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group
    Michael A Bookman
    Division of Medical Science, Fox Chase Cancer Center, Rockledge, PA, USA
    J Clin Oncol 21:283-90. 2003
    ..To evaluate the feasibility, toxicity, and efficacy of single-agent monoclonal antibody therapy targeting the human epidermal growth factor receptor 2 (HER2)/neu receptor in ovarian and primary peritoneal carcinoma...
  14. ncbi request reprint Focus on epithelial ovarian cancer
    Robert F Ozols
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Cell 5:19-24. 2004
  15. ncbi request reprint Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic
    M A Bookman
    Division of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Int J Gynecol Cancer 15:12-7. 2005
    ..Integration of dFdC with platinum and/or radiation should also be investigated...
  16. ncbi request reprint Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5
    M A Bookman
    Division of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Int J Gynecol Cancer 13:735-40. 2003
    ..Results from GOG158 will be reviewed, including an analysis of second-look surgical outcomes, followed by an update on the current status of GOG0182-ICON5...
  17. ncbi request reprint Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5
    M A Bookman
    Division of Medical Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Gynecol Cancer 13:149-55. 2003
    ..Results from GOG158 will be reviewed, including an analysis of second-look surgical outcomes, followed by an update on the current status of GOG0182-ICON5...
  18. ncbi request reprint Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
    M A Bookman
    Fox Chase Cancer Center, Department of Medical Oncology, Philadelphia, PA 19111, USA
    J Clin Oncol 16:3345-52. 1998
    ..Topotecan, a topoisomerase I inhibitor, was evaluated in a multicenter, phase II study of women with epithelial ovarian carcinoma who relapsed after one or two prior regimens that included platinum and paclitaxel...
  19. ncbi request reprint Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy
    M A Bookman
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Oncologist 4:87-94. 1999
    ..Early use of topotecan offers an effective and tolerable strategy that can prolong the platinum-free interval and optimize subsequent retreatment with platinum...
  20. ncbi request reprint Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells
    R J Schilder
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 17:2198-207. 1999
    ..To determine the safety and feasibility of delivering multiple cycles of front-line high-dose carboplatin and paclitaxel with hematopoietic peripheral-blood stem cell (PBSC) support...
  21. ncbi request reprint Using tumor registry resources in analyzing concordance with guidelines and outcomes
    M A Bookman
    Division of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Oncology (Williston Park) 14:104-7. 2000
    ..One strategy that can be used to facilitate a global outcomes program within the NCCN community calls for capitalizing on existing local database resources and experienced coding and data management staff...
  22. ncbi request reprint Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group
    M A Bookman
    Division of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Int J Gynecol Cancer 11:42-51. 2001
    ..The selection of candidate regimens for this trial illustrate the challenges of drug development in EOC...
  23. ncbi request reprint Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administration
    G P Adams
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Immunol Immunother 40:299-306. 1995
    ..06 microgram/ml, at the 48-h point. These results suggest that multiple high-dose administrations of radiolabeled 741F8 (sFv')2 may lead to the selective tumor localization of therapeutic radiation doses...
  24. pmc A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study
    Deborah K Armstrong
    Johns Hopkins Kimmel Cancer Center, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231 1000, USA
    Gynecol Oncol 105:667-71. 2007
    ....
  25. ncbi request reprint Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study
    Katherine Y Look
    Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Gynecol Oncol 92:93-100. 2004
    ....
  26. ncbi request reprint Progress in the management of gynecologic cancer: consensus summary statement
    Stephen A Cannistra
    Department of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Brigham and Women s Hospital, Dana Farber Cancer Institute, and Massachusetts General Hospital, Boston, USA
    J Clin Oncol 21:129s-132s. 2003
  27. pmc Speeding up the evaluation of new agents in cancer
    Mahesh K B Parmar
    Clinical Trials Unit, London, UK
    J Natl Cancer Inst 100:1204-14. 2008
    ..By using intermediate outcomes and testing a number of new agents (and combinations) simultaneously, the new design requires fewer patients. Three trials using this methodology are presented...
  28. ncbi request reprint Phase I escalation of gemcitabine combined with protracted oral etoposide in gynecologic malignancies: A Gynecologic Oncology Group study
    Agustin A Garcia
    Division of Medical Oncology, University of Southern California Norrris Comprehensive Cancer Center, Los Angeles 90089, USA
    Invest New Drugs 20:383-7. 2002
    ..This, combined with preclinical synergism, prompted the Gynecologic Oncology Group to determine the maximum tolerated dose (MTD) of this combination...
  29. ncbi request reprint Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study
    Steven C Plaxe
    Department of Gynecologic Oncology, University of California at San Diego, San Diego, California 92103, USA
    Gynecol Oncol 84:32-5. 2002
    ..The Gynecologic Oncology Group (GOG) performed a phase II trial of PZA to determine the response rate of this agent in patients with recurrent platinum-sensitive ovarian cancer...
  30. ncbi request reprint Intraperitoneal chemotherapy for ovarian cancer
    Robert F Ozols
    N Engl J Med 354:1641-3; author reply 1641-3. 2006
  31. ncbi request reprint Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel
    Robert F Ozols
    Gynecol Oncol 103:1-6. 2006
  32. ncbi request reprint Cervical cancer
    Benjamin E Greer
    J Natl Compr Canc Netw 6:14-36. 2008
  33. ncbi request reprint The use of radiation as a component of breast conservation therapy in National Comprehensive Cancer Network Centers
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:361-9. 2006
    ..We investigated rates of radiation use after breast conservation therapy (BCT) for patients treated for ductal carcinoma-in-situ (DCIS) or invasive breast cancer at National Comprehensive Cancer Network (NCCN) centers...
  34. pmc Selecting high priority quality measures for breast cancer quality improvement
    Michael J Hassett
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Med Care 46:762-70. 2008
    ..We sought to develop a simple, explicit strategy for prioritizing breast cancer quality measures based on their potential to highlight areas where quality improvement efforts could most impact a population...
  35. ncbi request reprint Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers
    Stephen B Edge
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    J Natl Cancer Inst 95:1514-21. 2003
    ..This study examined the extent and time trends of the use of SNB in stage I and II breast cancer patients...
  36. ncbi request reprint Uterine cancers
    Benjamin E Greer
    Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance, Seattle, WA, USA
    J Natl Compr Canc Netw 4:438-62. 2006
  37. ncbi request reprint A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors
    James A Posey
    Departments of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294 3300, USA
    Clin Cancer Res 8:3092-9. 2002
    ..This antibody is specific for a Lewis(Y) (Le(Y))-related carbohydrate antigen expressed on multiple carcinomas...